Jinesh and colleagues found that the SMAC mimetic compound-C was able to sensitize BC cells to BCG-stimulated neutrophils, which constitute the main type of immune cells recruited in response to BCG treatment to release TNF-α, TRAIL and FasL. Here, TNFSF10 is linked to breast cancer.